Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

– Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers – – Preliminary data on WTX-124 administered in combination with pembrolizumab show similar tolerability to WTX-124 monotherapy – – Additional details and data post abstract cut-off date to be presented at ASCO – – Company to host webcast to review these data on Monday, June 3, 2024, at 8:00 am ET – WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment...

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic and memory T cells associated with subsequent prolonged survival, and a beneficial effect on both injected and uninjected tumors (abscopal response) As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile NEEDHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE)...

Timbercreek Financial Declares May 2024 Dividend

Written by Customer Service on May 23, 2024. Posted in Public Companies.

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on June 14, 2024 to holders of Common Shares of record on May 31, 2024. The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees. Pursuant to the Plan and at the discretion of Timbercreek Capital Inc., the Manager, Common Shares will be acquired in the open market at prevailing prices or issued from treasury at 98 percent of the average market price (the “Average...

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

– 60% response rate observed among 10 evaluable patients – Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed – Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting website. The abstract presents interim clinical data from a cohort of 26 patients enrolled as of the...

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding MCLA-145 and an abstract regarding MCLA-129 at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. Both abstracts can be found on the 2024 ASCO® website. “We continue to be proud of our Multiclonics® technology platforms’...

MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Miami, Florida and Austin, Texas, May 23, 2024 (GLOBE NEWSWIRE) — Maquia Capital Acquisition Corporation, a special purpose acquisition company (Nasdaq: MAQC) (“Maquia”), and Immersed Inc., a Delaware corporation (“Immersed”), today announced that effective as of May 20, 2024 they mutually agreed to immediately terminate the previously announced Business Combination Agreement (the “Business Combination Agreement”),. Maquia intends to continue to pursue the consummation of a business combination with an appropriate target. Additional information about the termination of the Business Combination Agreement will be provided in a Current Report on Form 8-K to be filed by Maqua with the SEC and available at www.sec.gov. About Maquia Capital Acquisition Corporation Maquia Capital Acquisition Corporation is a blank check company formed...

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All Responses Remain Ongoing at a Median Follow-up of 21.7 Months in the Oral Presentation Data in Published Abstract and Upcoming Oral PresentationStrongly Support Ongoing TILVANCE-301 Phase 3 Trial SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline...

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Poster highlights durable disease stabilization lasting beyond treatment completion Results suggest a unique, multimodal mechanism of action that differs from other cancer therapeutics Favorable tolerability sets stage for Part 3 (dose optimization) of Phase 1 trial, already underway MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in patients with solid tumors. The data will be presented in a poster session on June 1, 9:00 AM-12:00 PM CDT (abstract...

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, will present interim results from the Company’s Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). The data...

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on May 23, 2024. Posted in Public Companies.

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024. The Company has two abstracts selected for oral presentation, including an updated presentation of investigator-assessed 12-month data from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and another presentation showcasing data from the Phase 1 trial of RP2 combined with nivolumab in advanced uveal melanoma. In addition, RP1 and RP2 are also featured in three trial-in-progress posters. Details for the presentations are...

Day: May 23, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice